SG178195A1
(en)
|
2009-07-31 |
2012-03-29 |
Sanofi Aventis Deutschland |
Long acting insulin composition
|
CA2769340C
(en)
*
|
2009-07-31 |
2018-09-11 |
Harald Rau |
Prodrugs comprising an insulin linker conjugate
|
CA2776723C
(en)
|
2009-10-29 |
2018-09-25 |
Ascendis Pharma As |
Sterilization of biodegradable hydrogels
|
CN102711733A
(zh)
|
2009-12-15 |
2012-10-03 |
阿森迪斯药物股份有限公司 |
瞬时连接于聚合物载体的干生长激素组合物
|
EP2525829A1
(en)
|
2010-01-22 |
2012-11-28 |
Ascendis Pharma A/S |
Dipeptide-based prodrug linkers for aromatic amine-containing drugs
|
WO2011089216A1
(en)
|
2010-01-22 |
2011-07-28 |
Ascendis Pharma As |
Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
|
EP2525831B1
(en)
|
2010-01-22 |
2019-05-15 |
Ascendis Pharma A/S |
Carrier-linked carbamate prodrug linkers
|
JP6017422B2
(ja)
|
2010-08-10 |
2016-11-02 |
エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ(ウペエフエル)Ecole Polytechnique Federale de Lausanne (EPFL) |
赤血球結合療法
|
US9517257B2
(en)
|
2010-08-10 |
2016-12-13 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Erythrocyte-binding therapeutics
|
US9850296B2
(en)
|
2010-08-10 |
2017-12-26 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Erythrocyte-binding therapeutics
|
EP2438930A1
(en)
|
2010-09-17 |
2012-04-11 |
Sanofi-Aventis Deutschland GmbH |
Prodrugs comprising an exendin linker conjugate
|
US10451897B2
(en)
|
2011-03-18 |
2019-10-22 |
Johnson & Johnson Vision Care, Inc. |
Components with multiple energization elements for biomedical devices
|
WO2012151051A1
(en)
*
|
2011-05-03 |
2012-11-08 |
Telik, Inc. |
Excipient compatibility with ezatiostat
|
EP2723357A4
(en)
*
|
2011-06-21 |
2015-04-01 |
Bvw Holding Ag |
MEDICAL DEVICE COMPRISING BOSWELLIC ACID
|
EP3643306A3
(en)
|
2011-08-12 |
2020-08-26 |
Ascendis Pharma A/S |
Carrier-linked prodrugs having reversible carboxylic ester linkages
|
AU2012296954B2
(en)
|
2011-08-12 |
2016-09-15 |
Ascendis Pharma A/S |
Carrier-linked treprostinil prodrugs
|
JP2014522878A
(ja)
|
2011-08-12 |
2014-09-08 |
アセンディス ファーマ エー/エス |
プロスタサイクリンの徐放組成物
|
CA2849192C
(en)
*
|
2011-10-12 |
2019-09-24 |
Ascendis Pharma Ophthalmology Division A/S |
Prevention and treatment of ocular conditions
|
CN104144705B
(zh)
*
|
2011-11-03 |
2017-03-01 |
拜耳知识产权有限责任公司 |
用于肽的可释放性连接的基于酪氨酸的连接体
|
US8857983B2
(en)
|
2012-01-26 |
2014-10-14 |
Johnson & Johnson Vision Care, Inc. |
Ophthalmic lens assembly having an integrated antenna structure
|
US20150087688A1
(en)
|
2012-04-25 |
2015-03-26 |
Ascendis Pharma A/S |
Prodrugs of hydroxyl-comprising drugs
|
WO2014002039A1
(en)
*
|
2012-06-27 |
2014-01-03 |
Shire Ag |
Amphetamine prodrugs
|
TR201816416T4
(tr)
|
2012-08-21 |
2018-11-21 |
Janssen Pharmaceutica Nv |
Risperidona yönelik antikorlar ve bunların kullanımı.
|
JP2015529199A
(ja)
|
2012-08-21 |
2015-10-05 |
オルソ−クリニカル ダイアグノスティクス,インコーポレイティド |
パリペリドンハプテンに対する抗体及びその使用
|
CA2882490A1
(en)
|
2012-08-21 |
2014-02-27 |
Ortho-Clinical Diagnostics, Inc. |
Antibodies to paliperidone and use thereof
|
PT2888234T
(pt)
|
2012-08-21 |
2018-02-22 |
Janssen Pharmaceutica Nv |
Haptenos de aripiprazol e seu uso em imunoensaios
|
ES2762105T3
(es)
|
2012-08-21 |
2020-05-22 |
Janssen Pharmaceutica Nv |
Anticuerpos para aripiprazol y uso de los mismos
|
CN104736567B
(zh)
|
2012-08-21 |
2019-09-03 |
詹森药业有限公司 |
阿立哌唑半抗原的抗体及其用途
|
EP3556759B1
(en)
*
|
2012-08-21 |
2023-11-29 |
Janssen Pharmaceutica NV |
Haptens of paliperidone
|
JP6374387B2
(ja)
|
2012-08-21 |
2018-08-15 |
ヤンセン ファーマシューティカ エヌ.ベー. |
リスペリドンハプテンへの抗体及びその使用
|
AU2013328785B2
(en)
*
|
2012-10-11 |
2016-07-21 |
Ascendis Pharma A/S |
Hydrogel prodrugs
|
MX363462B
(es)
*
|
2012-10-11 |
2019-03-25 |
Ascendis Pharma As |
Diagnostico, prevencion y tratamiento de enfermedades de la articulacion.
|
BR112015007778B1
(pt)
|
2012-10-11 |
2023-04-25 |
Ascendis Pharma Ophthalmology Division A/S |
Composição farmacêutica de profármacos neutralizantes de vegf ligados ao veículo para tratamento de condições oculares
|
EP2928501B1
(en)
|
2012-12-07 |
2020-05-06 |
Ascendis Pharma A/S |
Carrier-linked prostanoid prodrugs
|
US20140271885A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Intezyne Technologies, Inc. |
Copolymers for stable micelle formulations
|
US11116849B2
(en)
|
2013-04-22 |
2021-09-14 |
Ascendis Pharma A/S |
Hydrogel-linked prodrugs releasing tagged drugs
|
ES2950083T3
(es)
*
|
2013-04-22 |
2023-10-05 |
Ascendis Pharma As |
Hidrogeles modificados
|
WO2014205126A1
(en)
|
2013-06-19 |
2014-12-24 |
The Regents Of The University Of California |
Chemical structures for localized delivery of therapeutic agents
|
RU2543375C1
(ru)
*
|
2013-07-29 |
2015-02-27 |
Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Башкирский государственный университет" |
Комплексное соединение производного метилурацила с органической кислотой и способ его получения
|
CA2919892C
(en)
|
2013-08-12 |
2019-06-18 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extruded immediate release abuse deterrent pill
|
CA2925862A1
(en)
|
2013-10-01 |
2015-04-09 |
Glaxosmithkline Intellectual Property Development Limited |
Compounds for affinity chromatography and for extending the half-life of a therapeutic agent
|
EP3054982B1
(en)
*
|
2013-10-08 |
2019-05-01 |
Ascendis Pharma A/S |
Hydrogel-linked il-1ra prodrug
|
CN103554296B
(zh)
*
|
2013-10-12 |
2015-09-16 |
天津大学 |
一种亚油酸改性葡聚糖及制备高分子脂质体的方法
|
AU2014345511A1
(en)
|
2013-11-11 |
2016-05-12 |
Ascendis Pharma A/S |
Relaxin prodrugs
|
US9675607B2
(en)
*
|
2013-11-13 |
2017-06-13 |
Northwestern University |
Epimorphic regeneration and related hydrogel delivery systems
|
WO2015095391A1
(en)
|
2013-12-17 |
2015-06-25 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extruded extended release abuse deterrent pill
|
CN103706233A
(zh)
*
|
2013-12-17 |
2014-04-09 |
杨亮月 |
一种环氧乙烷零排放处理体系及方法
|
US9492444B2
(en)
|
2013-12-17 |
2016-11-15 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extruded extended release abuse deterrent pill
|
AU2015233084B2
(en)
|
2014-02-21 |
2020-12-17 |
Anokion Sa |
Glycotargeting therapeutics
|
US10946079B2
(en)
|
2014-02-21 |
2021-03-16 |
Ecole Polytechnique Federale De Lausanne |
Glycotargeting therapeutics
|
US10046056B2
(en)
|
2014-02-21 |
2018-08-14 |
École Polytechnique Fédérale De Lausanne (Epfl) |
Glycotargeting therapeutics
|
US10953101B2
(en)
|
2014-02-21 |
2021-03-23 |
École Polytechnique Fédérale De Lausanne (Epfl) |
Glycotargeting therapeutics
|
CA2942724C
(en)
|
2014-03-14 |
2022-12-13 |
The Regents Of The University Of California |
Tco conjugates and methods for delivery of therapeutic agents
|
AU2015289474B2
(en)
|
2014-07-17 |
2019-12-05 |
The Regents Of The University Of California |
Controllable self-annealing microgel particles for biomedical applications
|
US9707184B2
(en)
|
2014-07-17 |
2017-07-18 |
Pharmaceutical Manufacturing Research Services, Inc. |
Immediate release abuse deterrent liquid fill dosage form
|
AU2015299055C1
(en)
|
2014-08-06 |
2021-05-06 |
Ascendis Pharma A/S |
Prodrugs comprising an aminoalkyl glycine linker
|
US10381687B2
(en)
|
2014-08-21 |
2019-08-13 |
Johnson & Johnson Vision Care, Inc. |
Methods of forming biocompatible rechargable energization elements for biomedical devices
|
US9941547B2
(en)
|
2014-08-21 |
2018-04-10 |
Johnson & Johnson Vision Care, Inc. |
Biomedical energization elements with polymer electrolytes and cavity structures
|
US10361405B2
(en)
|
2014-08-21 |
2019-07-23 |
Johnson & Johnson Vision Care, Inc. |
Biomedical energization elements with polymer electrolytes
|
US9923177B2
(en)
*
|
2014-08-21 |
2018-03-20 |
Johnson & Johnson Vision Care, Inc. |
Biocompatibility of biomedical energization elements
|
US10361404B2
(en)
|
2014-08-21 |
2019-07-23 |
Johnson & Johnson Vision Care, Inc. |
Anodes for use in biocompatible energization elements
|
US9715130B2
(en)
|
2014-08-21 |
2017-07-25 |
Johnson & Johnson Vision Care, Inc. |
Methods and apparatus to form separators for biocompatible energization elements for biomedical devices
|
US9793536B2
(en)
|
2014-08-21 |
2017-10-17 |
Johnson & Johnson Vision Care, Inc. |
Pellet form cathode for use in a biocompatible battery
|
US10627651B2
(en)
|
2014-08-21 |
2020-04-21 |
Johnson & Johnson Vision Care, Inc. |
Methods and apparatus to form biocompatible energization primary elements for biomedical devices with electroless sealing layers
|
US9599842B2
(en)
|
2014-08-21 |
2017-03-21 |
Johnson & Johnson Vision Care, Inc. |
Device and methods for sealing and encapsulation for biocompatible energization elements
|
US9383593B2
(en)
|
2014-08-21 |
2016-07-05 |
Johnson & Johnson Vision Care, Inc. |
Methods to form biocompatible energization elements for biomedical devices comprising laminates and placed separators
|
EP3209282A4
(en)
|
2014-10-20 |
2018-05-23 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extended release abuse deterrent liquid fill dosage form
|
EP3210623B1
(en)
*
|
2014-10-24 |
2022-10-05 |
NOF Corporation |
Antibody-drug complex having cyclic benzylidene acetal linker
|
EP3220892B1
(en)
|
2014-11-21 |
2021-10-13 |
Ascendis Pharma Endocrinology Division A/S |
Long-acting growth hormone dosage forms
|
EP3303365A4
(en)
|
2015-05-29 |
2019-04-24 |
Ascendis Pharma Inc. |
PRODRUGS WITH A PYROGLUTAMATE LINKER
|
SG10201911226QA
(en)
|
2015-09-23 |
2020-01-30 |
Genentech Inc |
Optimized variants of anti-vegf antibodies
|
US11458041B2
(en)
*
|
2015-10-08 |
2022-10-04 |
Ocular Therapeutix, Inc. |
Punctal plug and bioadhesives
|
AU2016353345B2
(en)
|
2015-11-12 |
2021-12-23 |
University Of Virginia Patent Foundation |
Compositions and methods for vas-occlusive contraception and reversal thereof
|
CA3008809A1
(en)
|
2015-12-17 |
2017-06-22 |
Janssen Pharmaceutica Nv |
Antibodies to risperidone and use thereof
|
CN108697640A
(zh)
*
|
2015-12-18 |
2018-10-23 |
韩捷 |
一种可在生理条件下降解的水凝胶
|
US10413616B2
(en)
*
|
2015-12-23 |
2019-09-17 |
Viking Scientific, Inc. |
Hydrogel prodrug for treatment
|
WO2017142879A1
(en)
|
2016-02-16 |
2017-08-24 |
The Regents Of The University Of California |
Methods for immune system modulation with microporous annealed particle gels
|
US10345620B2
(en)
|
2016-02-18 |
2019-07-09 |
Johnson & Johnson Vision Care, Inc. |
Methods and apparatus to form biocompatible energization elements incorporating fuel cells for biomedical devices
|
JP7059195B2
(ja)
|
2016-03-01 |
2022-04-25 |
アセンディス ファーマ ボーン ディジージズ エー/エス |
Pthプロドラッグ
|
WO2017175200A1
(en)
|
2016-04-08 |
2017-10-12 |
The Regents Of The University Of California |
Modified hyaluronic acid hydrogels and proteins for the time-controlled release of biologic agents
|
CN105963792B
(zh)
*
|
2016-04-29 |
2019-03-22 |
深圳迈普再生医学科技有限公司 |
医用水凝胶组合物,医用水凝胶及其制备方法与应用
|
US11896671B2
(en)
|
2016-07-13 |
2024-02-13 |
Ascendis Pharma A/S |
Conjugation method for carrier-linked prodrugs
|
KR20240013849A
(ko)
|
2016-09-29 |
2024-01-30 |
아센디스 파마 본 디지즈 에이/에스 |
조절 방출 pth 화합물을 위한 투여 용법
|
KR20230170810A
(ko)
|
2016-09-29 |
2023-12-19 |
아센디스 파마 본 디지즈 에이/에스 |
낮은 피크 대 트로프 비를 가진 pth 화합물
|
KR102531327B1
(ko)
|
2016-09-29 |
2023-05-11 |
아센디스 파마 그로우쓰 디스오더스 에이/에스 |
조절 방출 cnp 아고니스트를 사용한 병용 요법
|
WO2018060311A1
(en)
|
2016-09-29 |
2018-04-05 |
Ascendis Pharma Bone Diseases A/S |
Incremental dose finding in controlled-release pth compounds
|
CN117582559A
(zh)
|
2016-12-29 |
2024-02-23 |
泰普治疗公司 |
用于治疗医疗植入物部位的方法和系统
|
AU2018230474B2
(en)
|
2017-03-10 |
2023-08-03 |
Georgia Tech Research Corporation |
FasL-engineered biomaterials with immunomodulatory function
|
AU2018240375C1
(en)
|
2017-03-22 |
2024-02-01 |
Ascendis Pharma A/S |
Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
|
JOP20190245A1
(ar)
*
|
2017-04-20 |
2019-10-15 |
Novartis Ag |
أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
|
CN108864258A
(zh)
*
|
2017-05-12 |
2018-11-23 |
北京康明海慧生物科技有限公司 |
具有抑制肿瘤功能的peg化多肽及其制备方法与应用
|
WO2018232176A1
(en)
|
2017-06-16 |
2018-12-20 |
The University Of Chicago |
Compositions and methods for inducing immune tolerance
|
CN107583104B
(zh)
*
|
2017-10-31 |
2020-12-01 |
无锡中科光远生物材料有限公司 |
一种可注射的用于脊柱修复的凝胶材料
|
AU2018360406A1
(en)
*
|
2017-11-02 |
2020-05-21 |
Tarsier Pharma Ltd |
Phosphorylcholine-tuftsin conjugate for treating ocular inflammation
|
CN107880288A
(zh)
*
|
2017-11-29 |
2018-04-06 |
桂林华诺威生物科技有限公司 |
一种透明质酸钠凝胶的制备方法
|
CN108096630B
(zh)
*
|
2018-01-29 |
2020-09-04 |
暨南大学 |
一种载淫羊藿苷和去铁胺的聚乳酸基骨组织支架及制备方法和应用
|
SG11202007524QA
(en)
|
2018-03-28 |
2020-09-29 |
Ascendis Pharma Oncology Div A/S |
Il-2 conjugates
|
FR3079421A1
(fr)
*
|
2018-03-28 |
2019-10-04 |
Edix Sa |
Presentations injectables, seringues et compositions a liberation prolongee et/ou controlee de lanreotide
|
CN110865130B
(zh)
*
|
2018-08-27 |
2023-08-22 |
北京海晶生物医药科技有限公司 |
一种盐酸奥洛他定及其有关物质的检测方法
|
WO2020064846A1
(en)
|
2018-09-26 |
2020-04-02 |
Ascendis Pharma A/S |
Novel hydrogel conjugates
|
TW202027794A
(zh)
*
|
2018-10-03 |
2020-08-01 |
瑞士商諾華公司 |
血管生成素樣3多肽之持續遞送
|
CN111077235B
(zh)
*
|
2018-10-19 |
2023-09-08 |
重庆医药工业研究院有限责任公司 |
一种测定2-[(2-甲基-5-溴苯基)甲基]-5-(4-氟苯基)噻吩杂质的方法
|
KR20210113272A
(ko)
|
2019-01-04 |
2021-09-15 |
아센디스 파마 온콜로지 디비전 에이/에스 |
선천 면역 작용제를 위한 지속되는 국소 약물 수준
|
TW202042844A
(zh)
*
|
2019-01-04 |
2020-12-01 |
丹麥商阿仙帝斯製藥公司 |
模式辨別受體(pattern recognition receptor)促效劑的共軛物
|
WO2020141225A1
(en)
|
2019-01-04 |
2020-07-09 |
Ascendis Pharma A/S |
Minimization of systemic inflammation
|
EP3906018A1
(en)
|
2019-01-04 |
2021-11-10 |
Ascendis Pharma Oncology Division A/S |
Induction of sustained local inflammation
|
US11471497B1
(en)
|
2019-03-13 |
2022-10-18 |
David Gordon Bermudes |
Copper chelation therapeutics
|
CN113924122A
(zh)
*
|
2019-06-07 |
2022-01-11 |
立卡达有限责任公司 |
水凝胶微粒中的可调降解
|
AU2020296297A1
(en)
|
2019-06-21 |
2021-12-16 |
Ascendis Pharma A/S |
Conjugates of heteroaromatic nitrogen-comprising compounds
|
WO2020254617A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Anti-ctla4 compounds with localized pk properties
|
WO2020254607A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Anti-ctla4 compounds with localized pd properties
|
WO2020254603A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma A/S |
CONJUGATES OF π-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS
|
TW202114738A
(zh)
|
2019-06-21 |
2021-04-16 |
丹麥商阿仙帝斯製藥公司 |
抗ctla4結合物
|
AU2020295724A1
(en)
|
2019-06-21 |
2021-12-02 |
Ascendis Pharma Oncology Division A/S |
Tyrosine kinase inhibitor conjugates
|
WO2020254612A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Controlled-release tyrosine kinase inhibitor compounds with localized pd properties
|
US20220304993A1
(en)
|
2019-06-21 |
2022-09-29 |
Ascendis Pharma A/S |
Conjugates of an electron-donating nitrogen or tertiary amine comprising compounds
|
WO2020254613A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Controlled-release tyrosine kinase inhibitor compounds with localized pk properties
|
WO2020261227A1
(en)
*
|
2019-06-26 |
2020-12-30 |
Biorchestra Co., Ltd. |
Micellar nanoparticles and uses thereof
|
AU2020300695A1
(en)
*
|
2019-07-03 |
2022-01-27 |
Molly Sandra Shoichet |
Hydrogel compositions and uses thereof
|
CN112168820B
(zh)
*
|
2019-07-05 |
2023-09-29 |
中国科学院生物物理研究所 |
SRCAP ATPase抑制剂在结直肠癌治疗中的应用
|
WO2021042043A1
(en)
*
|
2019-08-29 |
2021-03-04 |
Paul Douglas Godfrin |
Hydrogels as oral delivery dosage forms, methods of making and using same
|
TW202128141A
(zh)
*
|
2019-11-19 |
2021-08-01 |
美商盧伯利索先進材料有限公司 |
用雙縮二胍鹽化之聚胺酯組成物
|
AU2020419444A1
(en)
|
2020-01-03 |
2022-06-09 |
Ascendis Pharma A/S |
Conjugates undergoing intramolecular rearrangements
|
CN111138293B
(zh)
*
|
2020-01-10 |
2023-07-07 |
蚌埠丰原医药科技发展有限公司 |
一种用微通道反应器合成富马酸伊布利特中间体的方法
|
JP7451732B2
(ja)
|
2020-02-06 |
2024-03-18 |
オキュラ セラピューティクス,インコーポレイテッド |
眼疾患を治療するための組成物及び方法
|
KR102375663B1
(ko)
*
|
2020-03-24 |
2022-03-16 |
재단법인대구경북과학기술원 |
무손실 세포 염색 방법 및 장치
|
BR112022018815A2
(pt)
|
2020-03-25 |
2022-11-29 |
Ocular Therapeutix Inc |
Implante ocular contendo um inibidor de tirosina cinase
|
US20230241217A1
(en)
|
2020-05-04 |
2023-08-03 |
Ascendis Pharma A/S |
Hydrogel irradiation
|
CN113694261B
(zh)
*
|
2020-05-21 |
2022-09-09 |
江苏百赛飞生物科技有限公司 |
一种抗菌复合涂层及其制备方法和制品
|
US20210369651A1
(en)
*
|
2020-05-28 |
2021-12-02 |
Sollievo Pharmaceuticals, Inc |
Parenteral delivery of avizafone
|
AU2021286177A1
(en)
|
2020-06-03 |
2022-12-01 |
Ascendis Pharma Oncology Division A/S |
IL-2 sequences and uses thereof
|
US11739166B2
(en)
|
2020-07-02 |
2023-08-29 |
Davol Inc. |
Reactive polysaccharide-based hemostatic agent
|
WO2022029178A1
(en)
|
2020-08-05 |
2022-02-10 |
Ascendis Pharma A/S |
Conjugates comprising reversible linkers and uses thereof
|
EP4204439A1
(en)
|
2020-08-28 |
2023-07-05 |
Ascendis Pharma Oncology Division A/S |
Glycosylated il-2 proteins and uses thereof
|
AU2021349316A1
(en)
|
2020-09-28 |
2023-04-27 |
Ascendis Pharma Bone Diseases A/S |
Improvement of physical and mental well-being of patients with hypoparathyroidism
|
CN112316156B
(zh)
*
|
2020-10-27 |
2022-03-15 |
四川大学 |
具抗氧化和抗菌性的胶原蛋白修复膜、其制备方法及应用
|
KR102437315B1
(ko)
*
|
2020-11-02 |
2022-08-30 |
아주대학교산학협력단 |
하이브리드 하이드로겔 및 이의 생의학적 용도
|
AU2022246997A1
(en)
|
2021-04-01 |
2023-09-28 |
Ascendis Pharma A/S |
Use of long-acting growth hormone for treating inflammation-induced diseases
|
CN113304139B
(zh)
*
|
2021-06-30 |
2022-04-29 |
贵州医科大学 |
Viniferifuran在制备黄嘌呤氧化酶抑制药物中的应用
|
CN113398145B
(zh)
*
|
2021-07-02 |
2022-10-14 |
合肥康诺生物制药有限公司 |
含nad与氨氯地平的药物组合物及其用途
|
CN113461979A
(zh)
*
|
2021-07-19 |
2021-10-01 |
吉林大学 |
一种通过血红蛋白催化交联的仿贻贝类水凝胶的制备方法
|
AU2022409306A1
(en)
|
2021-12-13 |
2024-06-06 |
Ascendis Pharma Oncology Division A/S |
Cancer treatments with tlr7/8 agonists
|
CN114469926B
(zh)
*
|
2022-01-28 |
2023-06-27 |
吉林省健维天然生物科技有限公司 |
二氢槲皮素的新用途及二氢槲皮素水凝胶的制备方法
|
CN115109275B
(zh)
*
|
2022-08-29 |
2022-11-01 |
杭州艾名医学科技有限公司 |
一种动态交联可降解水凝胶、制备方法及应用
|
CN115444840B
(zh)
*
|
2022-09-15 |
2023-08-25 |
四川大学 |
一种前药、两性离子水凝胶及其制备方法、应用
|
CN115322397B
(zh)
*
|
2022-09-23 |
2024-04-30 |
福州大学 |
一种预防术后腹腔粘连的两性离子水凝胶及其制备方法
|
CN115537017B
(zh)
*
|
2022-09-27 |
2023-09-01 |
四川大学 |
一种水凝胶及其制备方法和应用
|
WO2024094673A1
(en)
|
2022-11-02 |
2024-05-10 |
Ascendis Pharma Bone Diseases A/S |
Pth treatment regimen comprising two pth compounds
|